Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in
both men and women worldwide. This is in spite of widespread, effective measures of …

Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15 …

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …

Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from
therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the …

Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with
chemotherapy is effective for patients with RAS wild type metastatic colorectal cancer …

Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to
sustained suppression of MAPK signaling and suppressed tumor growth in BRAF V600E …

Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor
(EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC) …

Functional activation of growth factors and receptors of the epidermal growth factor receptor
(EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer …

Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic
colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40 …